Cornerstone Robotics vs Saluda Medical
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $200M oversubscribed (Nov 2025) backed by Hong Kong Investment Corporation and sovereign wealth funds. China NMPA-approved. UK colorectal/urologic clinical trial launched.
About
Cornerstone Robotics is a surgical robotics company whose Sentire Endoscopic Surgical System uses multiple robotic arms to enable minimally invasive surgery with enhanced dexterity beyond single-arm laparoscopic systems. The company raised $200 million in an oversubscribed round in November 2025, backed by the Hong Kong Investment Corporation and global sovereign wealth funds. Sentire has received China National Medical Products Administration (NMPA) approval and launched UK clinical trials for colorectal and urologic procedures in 2025, with 2026 as its international commercialization ramp year.
Saluda Medical is the pioneer of closed-loop spinal cord stimulation (SCS); FDA-approved Evoke SCS system with real-time neural feedback; raised $100M in Jan 2025; received FDA clearance for automated EVA programming platform.
About
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US operations in Marlborough, Massachusetts), Saluda''s flagship product is the Evoke Spinal Cord Stimulation (SCS) System — the world''s first SCS system that senses and measures neural responses to stimulation (evoked compound action potentials, or ECAPs) and automatically adjusts therapy in real time based on each patient''s neurophysiological feedback. This closed-loop approach provides more precise, consistent pain relief compared to conventional open-loop SCS systems.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Cornerstone Robotics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.